TrialJournal for immunotherapy of cancer2026

Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.

Carlos Rojas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.